Prostate Epithelial Pten/TP53 Loss Leads to Transformation of Multipotential Progenitors and Epithelial to Mesenchymal Transition
Philip Martin(AstraZeneca (Singapore)), Kathleen Kelly(National Cancer Institute)
Cited by 100
Related Papers
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
|Journal for ImmunoTherapy of Cancer|2018|312